- DSMB Recommends Continuation without Modification for Third Time
- Safety Review Included 395 Patients
- Interim Survival Analysis Still Expected Early 2025 given Lower-Than-Expected Event Rate
- Low Event Rate Suggests Potential for Prolonged Survival
- Rapid Enrollment Positions Company for Enrollment Completion by Q1 2025; Earlier Than Expected
InflaRx Announces GOHIBIC (Vilobelimab) Selected By BARDA For Phase 2 Study On Acute Respiratory Distress Syndrome; One Of Three Investigational Therapies Chosen By U.S. Department Of Health And Human Services
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.